Skip to main content

Advertisement

Table 2 Univariate and multivariate Cox regression analysis

From: Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment

  Univariate HR (95% Cl) Multivariate
Model 1 HR (95% Cl) Model 2 HR (95% Cl)
Age 0.999 (0.976–1.022) 0.996 (0.970–1.023) 0.998 (0.972–1.025)
Female 1.266 (0.906–1.770) 1.152 (0.797–1.665) 1.162 (0.8031–1.682)
Education 0.961 (0.907–1.019) 0.954 (0.900–1.011) 0.961 (0.906–1.020)
APOE ε4 carrier 1.290 (0.896–1.858) 0.996 (0.674–1.470) 1.031 (0.700–1.520)
Cognition
 MMSE 0.821 (0.748–0.901)b NI NI
 CDR SB 1.593 (1.347–1.883)b 1.526 (1.276–1.824)b 1.531 (1.279–1.832)b
 ADAS-cog 11 1.118 (1.080–1.157)b 1.101 (1.061–1.144)b 1.104 (1.063–1.147)b
CSF markers
 CSF t-tau* 1.003 (1.000–1.006)a NI NI
 CSF p-tau** 1.012 (1.006–1.019)b 1.006 (1.000–1.013) 1.006 (1.000–1.013)
MRI
 MTA 1.682 (1.203–2.352)a 1.424 (0.997–2.034)a NI
 PA 2.244 (1.497–3.364)b 1.895 (1.239–2.897)b NI
 Atrophy pattern
  No atrophy Reference NI Reference
  MTA only 2.998 (1.443–6.227)a NI 3.178 (1.520–6.645)b
  PA only 3.126 (1.666–5.864)b NI 3.209 (1.693–6.080)b
  Both MTA and PA 3.814 (2.045–7.110)b NI 3.598 (1.909–6.783)b
  1. * Data for 7 subjects were not available
  2. ** Data for 1 subject were not available
  3. a p < 0.05
  4. b p < 0.001
  5. Model 1: adjusted for MTA, PA, age, sex, education, APOE ε4 carrier, ADAS-cog 11, CDR SB, and CSF p-tau
  6. Model 2: adjusted for MRI atrophy pattern (no atrophy, MTA only, PA only, both MTA and PA), age, sex, education, APOE ε4 carrier, ADAS-cog 11, CDR SB, and CSF p-tau
  7. ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive subscale, CDR SB Clinical Dementia Rating Sum of Boxes, CI confidence interval, CSF cerebrospinal fluid, HR hazard ratio, MMSE Mini Mental State Examination, MRI magnetic resonance imaging, MTA medial temporal lobe atrophy, NI not included, PA posterior atrophy, p-tau tau phosphorylated at threonine 181, t-tau total tau